Literature DB >> 1096218

Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients.

J Gerlach, K Thorsen, R Fog.   

Abstract

8 male schizophrenic patients participated in a double-blind, cross over study of the extrapyramidal side-effects of haloperidol and clozapine (acute dystonis, Parkinsonism and tardive dyskinesia), together with their effect on homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) in the cerebrospinal fluid (CSF). Haloperidol (9 mg/day) caused Parkinsonism, reduced tardive dyskinesias and increased the HVA concentration in the CSF. Clozapine (225 mg/day) had no effect on the neurological phenomena but reduced HVA and 5-HIAA concentrations in the CSF. During the discontinuation phase following the administration of haloperidol, tardive dyskinesia occurred or was aggravated; this did not occur after administration of clozapine. Accordingly, it is suggested that clozapine does not induce dopaminergic hypersensibility and, therefore, will not induce tardive dyskinesias.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1096218     DOI: 10.1007/bf00421473

Source DB:  PubMed          Journal:  Psychopharmacologia


  28 in total

1.  Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine.

Authors:  J Gerlach; H Simmelsgaard
Journal:  Psychopharmacology (Berl)       Date:  1978-10-31       Impact factor: 4.530

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  Long-term experience with clozapine in Denmark: research and clinical practice.

Authors:  J Gerlach; E O Jørgensen; L Peacock
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia--a retrospective study of 387 patients.

Authors:  D Naber; M Leppig; R Grohmann; H Hippius
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists.

Authors:  C A Altar; W C Boyar; A Wasley; S C Gerhardt; J M Liebman; P L Wood
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

6.  Blockade of acquisition of one-way conditioned avoidance responding by haloperidol and metoclopramide but not by thioridazine or clozapine: implications for screening new antipsychotic drugs.

Authors:  J R Blackburn; A G Phillips
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Effects of clozapine on CSF homovanillic acid in spasmodic torticollis.

Authors:  A Thiel; D Dressler; A Reimer; E Rüther
Journal:  J Neural Transm Gen Sect       Date:  1994

8.  Modulation of reward and aversion processes in the rat diencephalon by neuroleptics: differential effects of clozapine and haloperidol.

Authors:  D M Atrens; T Ljungberg; U Ungerstedt
Journal:  Psychopharmacology (Berl)       Date:  1976-08-26       Impact factor: 4.530

9.  Differential effects of haloperidol and clozapine on attention.

Authors:  M Cheal
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug.

Authors:  J A Severson; H E Robinson; G M Simpson
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.